Año: 2016
Journal Impact Factor (JIF): 8.2820
Categoría | Edición | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|---|
CELL BIOLOGY | SCIE | 26/190 | Q1 | T1 | D2 |
Año: 2017
Journal Citation Indicator (JCI): 1,610
Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
---|---|---|---|---|---|
CELL BIOLOGY | 29/198 | Q1 | T1 | D2 | 85,61 |
Año:
2016
CiteScore:
12,000
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
General Biochemistry,Genetics and Molecular Biology | 14/186 | Q1 | T1 | D1 |
SJR año:
2016
Factor de Impacto:
8,337
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Biochemistry, Genetics and Molecular Biology (miscellaneous) | 5/259 | Q1 | T1 | D1 |
Agencia | Código de Proyecto |
---|---|
AFA Insurance | - |
Ahlen Foundation | - |
European Research Council | - |
Goran Gustafsson Foundation | - |
Hallsten Foundation | - |
Helleday Foundation | - |
StratNeuro | - |
Swedish Cancer Society | - |
Swedish Pain Relief Foundation | - |
Swedish Research Council | - |
Torsten and Ragnar Soderberg Foundation | - |
Vertex Pharmaceuticals (Europe) Ltd. | - |
Vinnova | - |
# | Autor | Afiliación |
---|---|---|
1 | Sanjiv, K | Karolinska Institutet (Sweden) |
2 | Hagenkort, A | Karolinska Institutet (Sweden) |
3 | Calderon-Montano, JM | Karolinska Institutet (Sweden) |
4 | Koolmeister, T | Karolinska Institutet (Sweden) |
5 | Reaper, PM | Vertex Pharmaceuticals, Inc. (United States) |
6 | Mortusewicz, O | Karolinska Institutet (Sweden) |
7 | Jacques, SA | Karolinska Institutet (Sweden) |
8 | Kuiper, RV | Karolinska Institutet (Sweden) |
9 | Schultz, N | Karolinska Institutet (Sweden) |
10 | Scobie, M | Karolinska Institutet (Sweden) |
11 | Charlton, PA | Vertex Pharmaceuticals, Inc. (United States) |
12 | Pollard, JR | Vertex Pharmaceuticals, Inc. (United States) |
13 | Berglund, UW | Karolinska Institutet (Sweden) |
14 | Altun, M | Karolinska Institutet (Sweden) |
15 | Karolinska Institutet (Sweden) |